State Street Corp lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 830.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 136,622,812 shares of the biotechnology company’s stock after acquiring an additional 121,934,158 shares during the quarter. Biogen comprises about 0.9% of State Street Corp’s investment portfolio, making the stock its 18th biggest holding. State Street Corp owned 92.43% of Biogen worth $30,860,361,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ilmarinen Mutual Pension Insurance Co boosted its stake in Biogen by 1,401.9% during the third quarter. Ilmarinen Mutual Pension Insurance Co now owns 261,333 shares of the biotechnology company’s stock valued at $59,030,000 after buying an additional 243,933 shares in the last quarter. Resona Asset Management Co. Ltd. raised its position in Biogen by 1,540.4% in the third quarter. Resona Asset Management Co. Ltd. now owns 716,848 shares of the biotechnology company’s stock worth $161,922,000 after acquiring an additional 673,149 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. raised its position in Biogen by 16,563.2% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 22,162 shares of the biotechnology company’s stock worth $5,006,000 after acquiring an additional 22,029 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in Biogen in the 3rd quarter valued at about $2,192,000. Finally, GW&K Investment Management LLC lifted its holdings in Biogen by 898.3% in the 3rd quarter. GW&K Investment Management LLC now owns 2,286 shares of the biotechnology company’s stock valued at $516,000 after acquiring an additional 2,057 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.
Latest Biogen News
These are some of the BIIB news items that stood out recently:
- Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
- Neutral Sentiment: Analyst commentary is mixed overall: one report says analysts remain moderately upbeat and notes BIIB has outpaced broad benchmarks over the past year, while another says Alzheimer’s progress and M&A-related growth expectations may already be reflected in the valuation. Analyst outlook Rating downgrade
- Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article
Analyst Ratings Changes
BIIB has been the topic of a number of research reports. Robert W. Baird boosted their target price on shares of Biogen from $250.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. UBS Group upped their target price on Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Morgan Stanley increased their price target on Biogen from $231.00 to $238.00 and gave the company an “equal weight” rating in a research report on Thursday, October 29th. Needham & Company LLC restated a “buy” rating on shares of Biogen in a report on Wednesday. Finally, Wedbush upped their price objective on shares of Biogen from $212.00 to $225.00 and gave the company a “neutral” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Biogen presently has an average rating of “Moderate Buy” and a consensus price target of $255.45.
Read Our Latest Research Report on BIIB
Biogen Stock Performance
Shares of Biogen stock opened at $249.59 on Friday. Biogen Inc. has a 12 month low of $160.36 and a 12 month high of $261.00. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The stock has a market cap of $36.89 billion, a PE ratio of 106.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The business has a fifty day simple moving average of $236.83 and a 200-day simple moving average of $206.86.
Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the company posted $4.81 EPS. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Biogen Inc. will post 12.46 EPS for the current fiscal year.
Biogen Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Articles
- Five stocks we like better than Biogen
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
